Healthcare
Live Price
Offline$0.013
+0.00% today
1Y Change
-75.47%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vincerx Pharma, Inc. (VINC) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and down 75.5% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +15.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +15.9%, free cash flow +35.4% with operating margin -1138.6% and ROIC -588.6%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Stock Foundry combines VINC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VINC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VINC Max Drawdown
-92.42%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VINC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$16.6M
+57.7% YoY
Free Cash Flow
-$2.3M
+94.1% YoY
Revenue Growth
+0.0%
EPS Growth
+15.9%
Gross Margin
50.0%
Net Margin
-1216.7%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | -915K | -939K | -340K | -173K |
| Operating Income | -31M | -43M | -69M | -63M | -11M |
| EBITDA | -31M | -39M | -62M | -39M | -16M |
| Net Income | -30M | -40M | -65M | -39M | -17M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5M | 13M | 12M | 111M | 62M |
| Total Assets | 8M | 18M | 59M | 118M | 63M |
| Total Liabilities | 5M | 7M | 12M | 17M | 6M |
| Shareholder Equity | 3M | 11M | 48M | 100M | 25M |
| Total Debt | 0 | 3M | 3M | 4M | 0 |
| Net Debt | -5M | -10M | -8M | -107M | -62M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
+93.2% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
2M
+94.1% YoY
Key ratios
Gross Margin
50.0%
Operating Margin
-1138.6%
Net Margin
-1216.7%
ROE
-542.5%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.